Kornimate/medical-research-clean huggingface dataset:
characteristics and treatment patterns of patients with chronic obstructive pulmonary disease (copd), initiating tio+olo or other maintenance therapies in the us and the uk: a retrospective claims database study

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the primary objectives of the study are to use us and uk data to describe the characteristics of chronic obstructive pulmonary disease (copd) patients according to various demographic, lifestyle, clinical, and medication use.


Eligibility criteria:
inclusion criteria: * parent cohort -- copd diagnosis * child cohort -- any initiation of first maintenance therapy after july 1, 2015 * grandchild cohort -- any initiation of second maintenance therapy after august 2, 2015 exclusion criteria: - parent cohort * age \<40 on index date * any copd diagnosis in baseline * any use of long-acting muscarinic antagonists (lama), long-acting beta-agonists (laba), or inhaled corticosteroid (ics) in baseline * \<365 days of continuous medical and pharmacy coverage
the relationship between age and carpal tunnel size

Conditions: Carpal Tunnel

Summary: investigators hypothesis is that as human age increases, the size of the carpal tunnel decreases.

participants will be taken to a hand examination room where a portable ultrasound (us) machine is present. a previously determined wrist will be examined for each of the participants. the us will be used to obtain measurements of the subjects carpal tunnel and median nerve at multiple levels in order to define its size.

Eligibility criteria:
inclusion criteria: * greater than age 18 having bilateral wrists amenable to ultrasound examination. exclusion criteria: * active carpal tunnel syndrome, * history of carpal tunnel syndrome * any prior arm or hand surgery (including previous carpal tunnel release for any reason or previous surgery on the volar wrist) * distal radius fracture deformity * rheumatoid arthritis * open wounds or lesions of the hand or forearm * known congenital deformities of the upper extremity.
study of fludarabine + cyclophosphamide + tbi conditioning regimen for double units cord blood transplantation(cbt)in severe aplastic anemia(saa)

Conditions: Aplastic Anemia

Summary: severe aplastic anemia is a fatal disease and patients without hla matched siblings need alternative treatment option. cord blood transplantation (cbt) has become an alternative treatment means in various diseases, but it has not been proved to be good for severe aplastic anemia. double units cbt is proposed to have better engraftment potential and and we reported successful double units ucbt after engraftment failure with single unit with promising result. to increase the engraftment potential, fludarabine, cyclophosphamide plus tbi conditioning regimen for double units cord blood transplantation was proposed for the patient with severe aplastic anemia without hla-matched donor.


Eligibility criteria:
inclusion criteria: * diagnosis of severe aplastic anemia defined by any two or three peripheral blood criteria and either marrow criterion. * peripheral blood * neutrophils \< 0.5 x 109/l * platelets \< 20 x 109/l * corrected reticulocytes \< 1% * bone marrow * severe hypocellularity (\< 25%) * moderate hypocellularity (25-30%) with hematopoietic cells representing \< 30% of residual cells * no prior hematopoietic stem cell transplantation. * age: no limits. * performance status: ecog 0-2. * patients must be free of significant functional deficits in major organs, but the following eligibility criteria may be modified in individual cases. * heart: a shortening fraction \> 30%, ejection fraction \> 45%. * liver: total bilirubin \< 2 × upper limit of normal; alt \< 3 × upper limit of normal. * kidney: creatinine \ 60 ml/min/1.73m2. * patients must lack any active viral infections or active fungal infection. * no appropriate donor * appropriate cord blood is available: matched at least in 4/6 of a, b, dr loci. * patients (or one of parents if patients age \< 19) should sign informed consent. exclusion criteria: * pregnant or nursing women. * malignant or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy. * psychiatric disorder that would preclude compliance. * congenital aplastic anemia including fanconi anemia.

Keywords: fludarabine, cyclophosphamide, tbi, severe aplastic anemia, cord blood transplantation, pediatric
a study of dlx105-dmp in subjects with plaque psoriasis

Conditions: Plaque Psoriasis

Summary: a pilot, open-label study in subjects with mild-to-moderate plaque psoriasis to investigate the safety, tolerability, and preliminary efficacy of a four-week multidose regimen of dlx105-dmp administered to a target lesion


Eligibility criteria:
key inclusion criteria: * signed and dated informed consent. * subjects aged 18-75 years. * male subject, or if female, must be surgically sterile, post-menopausal, or using acceptable birth control. * stable chronic mild-to-moderate plaque psoriasis. key exclusion criteria: * non-plaque-type psoriasis only (e.g., pustular, erythrodermic and guttate psoriasis, palmar, or plantar) at screening. * drug-induced psoriasis (i.e., new onset or exacerbation from beta-blockers, calcium channel inhibitors or lithium) within 3 months prior to day 1. * ongoing use of psoriasis treatments or inadequate duration of washout prior to day 1
cec/epc and cardiovascular risk in renal transplant recipients

Conditions: Transplantation, Kidney; Cardiovascular Abnormalities; Cardiovascular Diseases

Summary: we believe that certain cells in the human body (circulating endothelial cells and endothelial progenitor cells) are related to risk of cardiovascular disease. it may be possible to measure levels of these cells in patients who have had a kidney transplant and predict their risk of developing cardiovascular disease.

coronary disease is one of the most common causes of morbidity and mortality in patients with known chronic renal insufficiency and those with end stage renal disease. consequently, early detection with markers such as circulating endothelial cells and endothelial progenitor cells has been studied in order to identify vascular function and assess overall cardiovascular risk. based on current research, there exists a notable increase in circulating endothelial cells (cec) and a reduction of endothelial progenitor cells (epc) with renal dysfunction due to endothelial damage. therefore circulating endothelial cells are a marker for cardiovascular health. renal transplant patients also possess a higher cardiovascular risk than the general population, but have known improvement in survival as compared to patients with esrd (end stage renal disease). in addition, because of the excellent outcomes, graft and patient survival and even acute rejection are no longer very useful endpoints for clinical studies. the tolerability of transplant drug regimens and the impact of these regimes on cardiovascular health in kidney transplantation has become, consequently, a new focus of research. currently, no clear long-term analysis has been fulfilled analyzing cec or epc in this group of patients. we hypothesize that cec can serve as biological markers for cardiovascular risk assessment in cadaveric and living renal transplant patients. we eventually hope measurement of these cells can serve as an endpoint in determining cardiovascular outcome in renal transplant patients. our present study is aimed to get an initial assessment of the kinetics of cec and epc in renal transplant recipients just prior to transplant and for the first two years post transplant.

Eligibility criteria:
inclusion criteria: * kidney transplant recipients * kidney/pancreas transplant recipients * age 18-80 exclusion criteria: * inability to return for follow-up visits * multiple organ transplant other than listed above

Keywords: transplantation cardiovascular renal
mobile integrated healthcare and community paramedicine

Conditions: Hospital Readmission; Pneumonia; Myocardial Infarction; COPD

Summary: background: initially conceived of as a method to address healthcare needs of underserved rural populations, mobile integrated healthcare and community paramedicine (mih/cp) is a new model of inter-professional, community-based outpatient healthcare delivery that primarily utilizes the resources and training of emergency medical services (ems) to fill gaps in local healthcare infrastructure, expanding existing scope of practice in most cases while not detracting from acute transport capabilities. although programs have been in existence since the early 1990s, there are few objective studies of the efficacy, safety, and cost-effectiveness of mih/cp programs, many of which are limited-scope pilot projects. the limited data already published on these measures by established programs shows substantial medicare charge-avoidances in patients enrolled in chf-readmission prevention and ems frequent user programs, and a significant reduction in emergency department visits overall, especially in austere environments. in summary, mih/cp is an attempt at formalization of long-standing practices to collaborate with and supplement other healthcare system components such as primary care and home health services. standardized, objective data collection and publication of results will be needed to support continuation and financial support of this emerging concept. objective/hypothesis: using the existing resources of the md-, rn- and paramedic-staffed lifespan pediatric and adult critical care transport (lifepact) service, investigators aim to study whether implementation of an mih/cp pilot program tailored to the needs of an urban, underserved population in providence, rhode island, will reduce the rate of 30-day hospital readmissions for patients after discharges for community-acquired pneumonia, acute mi, and copd. in addition, investigators will study whether such a program is considered to be safe (in terms of not increasing the number of adverse events post-discharge for patients or compromising the efficacy of the lifepact transport role) and considered satisfactory by patients (rated comparably to visits by other outpatient health care services such as vna services).


Eligibility criteria:
inclusion criteria: * current inpatient/observation status for: nstemi; chf; pna (community or hcap); copd; wound infection or complication, * english speaking, * not pregnant, * not incarcerated, * able to maintain clinical sobriety for informed consent and home visitation., * no unstable psychiatric conditions (patients may be under treatment for mental health conditions as long as their symptoms are controlled)., * accessible and reliable place of residence that is not a nursing home or "on the street" location. (homeless patients are eligible as long as they have consistent access to a domicile that can provide shelter and privacy)., * no anticipated vna or home care within 24-36 hours of visit, * ages 18-80
prasugrel vs. ticagrelor on myocardial injury in stemi

Conditions: ST Elevation Myocardial Infarction

Summary: the investigators propose to perform a randomized clinical trial comparing prasugrel vs. ticagrelor in 60 patients with st elevation acute myocardial infarction (stemi) undergoing primary percutaneous coronary intervention. the principal objective of the study would be analyzing the difference in myocardial infarction size measured by cardiac magnetic resonance at 6 months

dual antiplatelet therapy consisting of aspirin and one of the p2y12 receptor inhibitors is the mainstay of treatment for patients with st elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. prasugrel or ticagrelor have actually shown to be superior to clopidogrel improving the prognosis of these patients. however, the industrial interest has avoided any direct comparison between these two antiplatelets. comparison is of great interest considering that only ticagrelor has shown to significantly reduce mortality. as ticagrelor may exert off-target effects through adenosine-related mechanisms, the investigators aimed to investigate whether ticagrelor reduces myocardial injury to a greater extent than prasugrel in patients with revascularized stemi. patients with acute stemi undergoing primary percutaneous coronary revascularization within 6 hours of chest pain, will be randomized to (1) prasugrel (a 60 mg oral loading and a 10-mg dailiy maintenance dose) or to (2) ticagrelor (a 180 mg loading dose and a 90 mg twice daily maintenance dose). the predefined primary end point is infarct sieze on magnetic resonance imaging at the end of the study (6 months). magnetic resonance will be performed at day 1, day 7 and moth 6. platelet reactivity, biomarkers and clinical outcomes will also be assesed.

Eligibility criteria:
inclusion criteria: * age 18 years or older and equal or less than 75 years * symptom onset within 12 hours before random assignment * chest pain lasting more than 30 minutes * st-segment elevation of at least 0.1 mv in at least 2 limb leads, st-segment elevation of at least 0.2 mv in 2 or more contiguous precordial leads, or left bundle-branch block or paced rhythm * time from symptoms onset to randomization less than 6 hours * no severe heart failure (killip class \<3) * informed, written consent exclusion criteria: * history of myocardial infarction with q wave * history of surgical or percutaneous coronary revascularization * cardiogenic shock, defined as a systolic blood pressure \<90 mm hg with no response to fluid administration or \<100 mm hg in patients with supportive treatment and no bradycardia * history of stroke * history of bronchial asthma * symtomatic sinusal bradicardia or advance av block * history of hypersensitivity to aspirin, prasugrel or ticagrelor or contraindication to the doses established in the study * patients pretreated with 600 mg of clopidogrel or more * contraindication for the use of gadolinium during the magenitc resonance

Keywords: primary angioplasty prasugrel ticagrelor stemi cardiac magnetic resonance infarct size infarct injury
developing risk prediction model and testing the effect of dual task walking on improving cognitive function in patients with colorectal cancer

Conditions: Colorectal Cancer

Summary: the aims of this three-year study are to explore cognitive function under different stages of colorectal cancer (crc) and its related factors; and understand its disturbance and coping process caused by cancer-induced cognitive impairment (cici) from patient perspective; and further to test effect of dual-task walking on improving cognitive function in crc patients.

developing risk prediction model of mild cognitive impairment in patients with colorectal cancer from active treatment to survivor by exploring the effect of surgery and chemotherapy on cici, and to identify high risk population; and testing the effect of dual-task walking on improving cognitive function (memory, executive function and attention) in crc patients.

Eligibility criteria:
inclusion criteria: * patients with newly diagnosed stage i to iii colorectal cancer and montreal cognitive assessment (moca) \< 24. exclusion criteria: * patients with cancer other than colorectal cancer or have cancer recurrence.

Keywords: colorectal cancer cognitive impairment chemotherapy dual-task walking
effects of 800mg of rhodiola rosea in attention in adults with attention-deficit/hyperactivity disorder

Conditions: Attention Deficit Hyperactivity Disorder

Summary: this study evaluates the use of rhodiola rosea in the attention of adults with attention deficit/hyperactivity disorder (adhd). half of participants will receive rhodiola rosea 800mg, while the other half will receive 800mg of placebo.

the evaluation of new therapies in adults with attention deficit/hyperactivity disorder (adhd) may be clinically useful. rhodiola rosea is an herbal medicine used for centuries in various medical conditions. many randomized controlled trials have evaluated its usefulness in stress and fatigue. there were benefits in attention in some of these studies. mild side effects and beneficial antioxidant properties make reasonable an assessment of its potential benefits in adults with adhd. to our knowledge, rhodiola rosea has never been studied in adults with adhd.

Eligibility criteria:
inclusion criteria: * fulfillment of diagnostic and statistical manual of mental disorders, fifth edition, (dsm-5) diagnostic criteria for adhd in adults * intelligence quotient (iq) above 70 * eligibility to rhodiola rosea exclusion criteria: * clinical contraindication to rhodiola rosea * any unstable chronic illness without proper treatment (hypertension, heart, kidney or liver disease, etc) * any significant neurological disease (delirium, dementia, epilepsy, aids, head trauma, multiple sclerosis, stroke, etc) * unstable psychiatric comorbidities requiring immediate treatment (risk of suicide, current substance use disorder, etc.) * pregnant, nursing or absence of reliable contraception * current use of nicotine (\<30 days) * use of anticoagulants * current use of any psychoactive drug (\<30 days) * prior use of stimulants * current or lifetime psychosis * current or lifetime bipolar disorder

Keywords: adhd adults treatment rhodiola
cholecystitis from a microbiological and histopathological perspective

Conditions: Calculous Cholecystitis; Antibiotic Resistant Infection; Gallbladder Inflammation

Summary: the aim of this project is to investigate the presence of bacteria in the gallbladder wall and the bile in patients undergoing cholecystectomy, to determine if the standard empirical antibiotic treatment used currently is effective against the most common pathogens.

the investigators will compare two groups of patients; patients with acute calculous cholecystitis undergoing acute laparoscopic cholecystectomy and patients without cholecystitis undergoing elective laparoscopic cholecystectomy. secondly, the investigators wish to investigate if the presence of bacteria correlates with the grade of inflammation, and whether this can predict when cholecystitis is caused by infection. in a clinical setting, this can provide important knowledge regarding the choice of antibiotics currently used to treat and prevent infection in the gallbladder. the investigators will conduct two studies, one investigating the bacteria in bile and in the gallbladder wall and the resistens of the bacteria to antibiotics and another study investigating the histopathology of the gallbladder wall to see if the bacteria present is the cause of inflammation or an actual infection.

Eligibility criteria:
inclusion criteria: * age above 18 years * signed consent form * patients having cholecystectomy performed at the department of surgery, sygehus lillebælt, kolding. exclusion criteria: * administration of any type of antibiotics one month prior to surgery in the control group. * previous instrumentation of the bileducts * previous clinical acute cholecystitis treated conservatively with antibiotics patients will be precluded from the studypopulation in cases of pperioperative perforation of the gallbladder, or conversion to open cholecystectomy or in cases of failed attempts to extract bile or samples from the gallbladder wall.
impact of immunoscore colon test on adjuvant therapeutic strategy in non-metastatic colon cancer

Conditions: Colonic Neoplasms

Summary: immunoscore colon test (ict) will be applied on tumor samples from curative surgery. in the multidisciplinary meeting (mm) evaluating the participant adjuvant strategy, a first decision will be taken, based on the participant medical record only. ict will then be disclosed and the mm will take a second decision. the aim of the study is to observe if the ict result modifies the treatment decision.

on previous studies, immunoscore colon test identified subgroups of stage ii and iii colon cancer patients whose chemotherapy could be adjusted. the study hypothesis is that immunoscore colon test will modify the therapeutic decision in mm. with alpha and beta at 5% and p0=10% modification rate, the participating investigators need to include 280 participants, 140 in each cohort (stage ii and stage iii). participants will have tumor samples from their curative surgery tested with immunoscore colon. when the patients are evaluated in mm, a first therapeutic decision will be taken before disclosing the test result. ict result will then be communicated and a second decision will be taken.

Eligibility criteria:
inclusion criteria: * cytologically/histologically proven colon adenocarcinoma * non-metastatic cancer * stage ii or iii adenocarcinoma * surgical resection of primitive tumor within 6 weeks of multidisciplinary meeting * no macroscopic or microscopic proof of residual disease during surgery (r0 margins) * available surgical material: ffpe tumor samples * post-operative adjuvant chemotherapy considered during multidisciplinary meeting * age ≥18 years * eastern cooperative oncology group (ecog) performance status ≤2 * patient having signed a written informed consent prior to any trial specific procedures * patient affiliated to the social security system or equivalent exclusion criteria: * other invasive cancer within 5 years of the colon cancer diagnosis, except for adequately treated basal cell carcinoma or squamous cell skin carcinoma or in sity cervical carcinoma * patients for which adjuvant chemotherapy is contra-indicated * any previous systemic or loco regional anticancer therapy for the studied colon cancer (e.g. neoadjuvant therapy) * patient enrolled or planned to be enrolled in another clinical trial that may influence the therapeutic decision * any psychological, social or geographical issue that may hinder the patient's understanding of the study or the study conduct * person deprived of liberty or under the authority of a legal guardian * person unable to understand the study or to comply with the protocol procedures

Keywords: immunoscore adjuvant prospective colon